OrigiMed announced that the Human NTRK1/2/3 Genomic Alteration Testing Kit has been granted the Special Review Procedure for Innovative Medical Devices by the Center for Medical Device Evaluation of NMPA.
OrigiMed, a China-based leading precision medicine company and Takeda, a global biopharmaceutical company announced their strategic partnership to develop a genomic-based precision medicine platform during the 3rd China International Import Expo.
Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions.
With fast advances in the medical industry, on May 11, 2019, the third OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy was successfully held in Guangzhou.
OrigiMed (Shanghai) Co., Ltd., (OrigiMed) has formally announced the completion of its Series B financing.
5th Floor, Building 3, 115 Xinjun Ring Road, Minhang District, Shanghai
Floor 4, Information Building 2, Zhaolou Road 3576 , Pujiang Town, Minhang District, Shanghai
Service Hours：9:00-18:00 Monday to Friday (except statutory holidays)
We will reply you as soon as we receive the email.